RAFFA WEALTH MANAGEMENT, LLC’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-251
Closed -$9.75K 1176
2025
Q3
$9.75K Sell
251
-1
-0.4% -$36 ﹤0.01% 373
2025
Q2
$8.49K Hold
252
﹤0.01% 409
2025
Q1
$8.01K Hold
252
﹤0.01% 351
2024
Q4
$9.78K Hold
252
﹤0.01% 329
2024
Q3
$11.3K Hold
252
﹤0.01% 301
2024
Q2
$10.5K Hold
252
﹤0.01% 436
2024
Q1
$11.5K Hold
252
﹤0.01% 410
2023
Q4
$11.6K Hold
252
﹤0.01% 272
2023
Q3
$10.2K Hold
252
﹤0.01% 275
2023
Q2
$12.2K Hold
252
﹤0.01% 253
2023
Q1
$12.4K Hold
252
﹤0.01% 263
2022
Q4
$12.7K Hold
252
0.01% 252
2022
Q3
$12.6K Hold
252
0.01% 246
2022
Q2
$12.3K Hold
252
0.01% 258
2022
Q1
$15.1K Hold
252
0.01% 240
2021
Q4
$20K Hold
252
0.01% 224
2021
Q3
$22.3K Hold
252
0.01% 181
2021
Q2
$25.1K Hold
252
0.01% 180
2021
Q1
$22.6K Buy
+252
New +$24.9K 0.01% 186

Other funds holding GNOM

RAFFA WEALTH MANAGEMENT, LLC's GNOM Position: Q4 2025 in Review

RAFFA WEALTH MANAGEMENT, LLC sold out of Global X Genomics & Biotechnology ETF (GNOM) in Q4 2025, closing a stake of 251 shares — an estimated $9.75K sold.

RAFFA WEALTH MANAGEMENT, LLC first reported a position in GNOM in Q1 2021 and held it in 19 quarters. The position peaked at $25.1K in Q2 2021. 40 funds tracked by Wall St. Rank hold GNOM as of Q4 2025.

  • RAFFA WEALTH MANAGEMENT, LLC reported no remaining Global X Genomics & Biotechnology ETF position as of Q4 2025 after selling out during the quarter.
  • RAFFA WEALTH MANAGEMENT, LLC sold 251 Global X Genomics & Biotechnology ETF shares in Q4 2025, an estimated $9.75K.
  • RAFFA WEALTH MANAGEMENT, LLC first reported a position in Global X Genomics & Biotechnology ETF in Q1 2021 and held it in 19 quarters.
  • RAFFA WEALTH MANAGEMENT, LLC's Global X Genomics & Biotechnology ETF position peaked at $25.1K in Q2 2021.
  • 40 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q4 2025.

Based on RAFFA WEALTH MANAGEMENT, LLC's 13F filing for Q4 2025, filed 27 Jul 2026.